Next-generation
protease inhibitors

Bringing to patients new antibody-peptide conjugate therapies
to treat cancer and other challenging diseases

Bringing to patients new antibody-peptide
conjugate therapies to treat cancer
and other challenging diseases

Discover

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We are based in Lausanne, at the heart of Western Switzerland’s Health Valley: a cluster of life sciences companies, research centers, top-ranking university hospitals and innovation support structures.

Vision

To become the preferred partner for developing Antibody-Peptide Inhibitor Conjugates (APIC), a new drug modality enabling the creation of superior treatments in several disease areas by overcoming challenges of on-target & off-tissue toxicity.

Mission

Founded with the mission to advance an early stage drug development pipeline while investing in a drug discovery platform for supporting novel clinical research.

APICore drug discovery platform for targeted protease inhibitors

Our APICore drug discovery platform enables the development of first- and best-in-class APIC therapeutics targeting proteases. It combines the precision of targeted carriers with the potency and selectivity of peptide inhibitors to address the on-target and off-tissue toxicity limitations associated with conventional small-molecule inhibitors.

As described in our 2024 scientific publication, APICs are potent and selective protease inhibitors engineered to become active only on specific target cells, including tumor cells. Our approach enables the rapid design of an initial drug hit, followed by the screening of optimized non-natural peptide inhibitor variants with enhanced potency and specificity. Once a lead inhibitor is selected, it is linked to a targeted carrier to support efficient delivery to the desired cells.

All the advantages of APIC therapies

First-in-class protease inhibitors to treat cancer and more
Target specificity enables a strong safety profile
Cell-targeted delivery reduces on-target and off-tissue toxicity
Drug discovery platform for the development of novel protease inhibitors

Pre-clinical pipeline

Our pre-clinical pipeline includes 4 first-in-class drug candidates targeting cathepsin proteases B, S, K & L with in vivo proof of concept preclinical data in lymphoma and solid tumors. Our drug candidates have pipeline-in-a-product potential in oncology, osteoporosis and autoimmune indications. Our selected lead indications are lung adenocarcinoma and osteoporosis.

Pipeline overview